189 related articles for article (PubMed ID: 32399958)
1. Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
Cathomas R; Schardt J; Pless M; Llado A; Mach N; Riklin C; Haefeli J; Fear S; Stenner F
Swiss Med Wkly; 2020 May; 150():w20223. PubMed ID: 32399958
[TBL] [Abstract][Full Text] [Related]
2. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
Merseburger AS; Castellano D; Powles T; Loriot Y; Retz M; Voortman J; Huddart RA; Gedye C; Van Der Heijden MS; Gurney H; Ong M; de Ducla S; Pavlova J; Fear S; Sternberg CN
J Urol; 2021 Aug; 206(2):240-251. PubMed ID: 33835866
[TBL] [Abstract][Full Text] [Related]
4. Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.
Sternberg CN; Loriot Y; Choy E; Castellano D; Lopez-Rios F; Banna GL; Zengerling F; De Giorgi U; Gedye C; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Retz M; Gamulin M; Geczi L; Huddart RA; Calabrò F; Kandula G; Skamnioti P; Merseburger AS
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38839505
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.
Loriot Y; Sternberg CN; Castellano D; Oosting SF; Dumez H; Huddart R; Vianna K; Alonso Gordoa T; Skoneczna I; Fay AP; Nolè F; Massari F; Brasiuniene B; Maroto P; Fear S; Di Nucci F; de Ducla S; Choy E
Eur J Cancer; 2020 Oct; 138():202-211. PubMed ID: 32905959
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D; Ölmez ÖF; Sümbül AT; Artaç M; Özhan N; Akar E; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Yılmaz U; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S
Eur Urol Focus; 2021 Sep; 7(5):1061-1066. PubMed ID: 33008789
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
van der Heijden MS; Loriot Y; Durán I; Ravaud A; Retz M; Vogelzang NJ; Nelson B; Wang J; Shen X; Powles T
Eur Urol; 2021 Jul; 80(1):7-11. PubMed ID: 33902955
[TBL] [Abstract][Full Text] [Related]
11. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
Bamias A; Merseburger AS; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100152. PubMed ID: 33984672
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Perez-Gracia JL; Loriot Y; Rosenberg JE; Powles T; Necchi A; Hussain SA; Morales-Barrera R; Retz MM; Niegisch G; Durán I; Théodore C; Grande E; Shen X; Wang J; Nelson B; Derleth CL; van der Heijden MS
Eur Urol; 2018 Mar; 73(3):462-468. PubMed ID: 29273410
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
15. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Sonpavde GP; Sternberg CN; Loriot Y; Marabelle A; Lee JL; Fléchon A; Roubaud G; Pouessel D; Zagonel V; Calabro F; Banna GL; Shin SJ; Vera-Badillo FE; Powles T; Hellmis E; Miranda PAP; Lima AR; Emeribe U; Oh SM; Hotte SJ
Eur J Cancer; 2022 Mar; 163():55-65. PubMed ID: 35042068
[TBL] [Abstract][Full Text] [Related]
16. Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
Díaz Acedo R; Galvan Banqueri M; Artacho Criado S; Fernández Parra EM; Jiménez Galán R; Gago Sánchez AI; Marín Pozo JF; Martínez Bautista MJ
Int J Clin Pharm; 2024 Apr; 46(2):382-389. PubMed ID: 38112892
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
Sotelo M; Alonso-Gordoa T; Gajate P; Gallardo E; Morales-Barrera R; Pérez-Gracia JL; Puente J; Sánchez P; Castellano D; Durán I
Clin Transl Oncol; 2021 Apr; 23(4):882-891. PubMed ID: 32897497
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
[TBL] [Abstract][Full Text] [Related]
19. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
Bedke J; Merseburger AS; Loriot Y; Castellano D; Choy E; Duran I; Rosenberg JE; Petrylak DP; Dreicer R; Perez-Gracia JL; Hoffman-Censits JH; Van Der Heijden MS; Pavlova J; Thiebach L; de Ducla S; Fear S; Powles T; Sternberg CN
Eur Urol Focus; 2021 Sep; 7(5):1084-1091. PubMed ID: 33168461
[TBL] [Abstract][Full Text] [Related]
20. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
Loriot Y; Petrylak DP; Rezazadeh Kalebasty A; Fléchon A; Jain RK; Gupta S; Bupathi M; Beuzeboc P; Palmbos P; Balar AV; Kyriakopoulos CE; Pouessel D; Sternberg CN; Tonelli J; Sierecki M; Zhou H; Grivas P; Barthélémy P; Tagawa ST
Ann Oncol; 2024 Apr; 35(4):392-401. PubMed ID: 38244927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
